Roche to shed 100 jobs in diabetes Dx revamp

Despite Roche's ($RHHBY) continued diagnostics growth, the company has struggled to turn its diabetes unit around, and now it plans to slash 100 jobs and restructure the operation. Report

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.